Dr. Li Reviews Afatinib Data From the LUX-Lung 3 Trial
January 17th 2013Tianhong (Tina) Li, MD, PhD, from the UC Davis Comprehensive Cancer Center, discusses results from the LUX-Lung 3 trial that examined afatinib as a first-line treatment for patients with EGFR-positive advanced lung adenocarcinoma.
Read More